Earnings call · Apr–Jun 2026
Gaudium IVF and Women Health Limited
Apr–Jun 2026 revenue grew 9.1% to ₹19.4 crore but profit fell as management invested heavily in expansion & AI technology marketing. Management guided 30% FY27 revenue growth & sustained margins by year-end.
The full notes: the guidance, numbers & KPIs, strategy, outlook, risks, what analysts asked.
Premium opens every call in full: the notes, the marked passages, search & topic jumps, for every company that files a transcript.
From the company
- Surrogacy Act.
- Rakesh Sharma
- Jyotish Nair
Questions came from
- ArmanBlue Sky Fintech
- Vileh RaiKamayaKya Wealth Management
- Anuj GoyalBastion Research
- Manish KelaSwastik Investments
- Raman KVSequent Investments
- Jyotish NairMoat Financial Services
- Priyansh MiriNGP Family Office
Topics in this call
Opening remarks
Surrogacy Act.
So as we all know that this Act was introduced in 2022 and is in various phases of implementation across the country. We as one of the leaders are quite sure that when full implementation is there, there will be more and more consolidation in the industry and the organized player share is going to rise.
Nearly 27.5 million couples in India are affected by infertility and yet around 3 lakhs IVF cycles are performed annually. So imagine what a huge amount of untapped market is lying there. Add to this delayed parenthood, rising awareness, a steadily reducing stigma, and a very meaningful medical tourism opportunity where the cost of an IVF cycle in India is roughly 1/5th of what it is in the United States
Read the whole call: 173 paragraphs, 15 analysts' questions with every answer, 8 marked passages.
Premium opens every call in full: the notes, the marked passages, search & topic jumps, for every company that files a transcript.
The transcript as the company filed it on BSE. Our own rules split it into speakers & sections; an unusual layout can trip them, so check the original PDF for anything important. Not a recommendation.